Sanofi (NYSE:SNY) was downgraded by research analysts at Bank of America from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports.

Other equities analysts have also recently issued reports about the company. Argus restated a “buy” rating and set a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a report on Wednesday, November 15th. upgraded Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Finally, Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. Sanofi currently has a consensus rating of “Hold” and a consensus price target of $53.50.

Shares of Sanofi (NYSE:SNY) traded down $0.34 during mid-day trading on Wednesday, reaching $43.17. The company had a trading volume of 1,495,094 shares, compared to its average volume of 1,502,720. Sanofi has a 1-year low of $38.45 and a 1-year high of $50.65. The company has a market capitalization of $111,349.80, a PE ratio of 13.93, a PEG ratio of 2.44 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16.

Several large investors have recently modified their holdings of SNY. Southpoint Capital Advisors LP acquired a new position in shares of Sanofi during the second quarter worth approximately $57,492,000. BlackRock Inc. raised its position in shares of Sanofi by 47.6% during the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock worth $107,100,000 after purchasing an additional 720,523 shares during the period. Boston Partners raised its position in shares of Sanofi by 6.2% during the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock worth $431,429,000 after purchasing an additional 503,799 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Sanofi during the second quarter worth approximately $22,558,000. Finally, Fisher Asset Management LLC raised its position in shares of Sanofi by 3.3% during the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after purchasing an additional 443,799 shares during the period. 9.09% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Sanofi (SNY) Cut to Neutral at Bank of America” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/06/sanofi-sny-cut-to-neutral-at-bank-of-america.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.